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The primary goal of this study was to determine if the ability
to undergo catch-up growth following a transient injury is
preserved in an experimental model of moderate chronic
renal failure (CRF) and the effect of growth hormone (GH)
administration on such phenomenon. Young rats were
subtotally nephrectomized (days 0 and 4) (Nx). From days 11
to 13, food intake was restricted in subgroups of Nx and
control (C) rats (NxR and CR). After refeeding, subgroups of
NxR and CR rats received GH from days 14 to 20 (NxRGH and
CRGH). Rats were killed on days 14 (C, CR, Nx, NxR), 17 and 21
(C, CR, CRGH, Nx, NxR, NxRGH), and 36 (C, CR, Nx, NxR).
Longitudinal growth rate was measured by osseous front
advance in the proximal tibiae. With refeeding, growth rate
of CR, NxR, and NXrGH rats became significantly greater than
that of C, indicating catch-up growth. This occurred later and
with lower growth rate in NxR than in CR rats, whereas the
characteristics of catch-up growth in CR and NxRGH animals
were similar. Changes in growth rate were associated with
modifications in the morphology and proliferative activity of
growth cartilage. We conclude that catch-up growth occurs
in renal insufficiency but follows a different pattern from
that observed with normal renal function. GH treatment
normalizes the pattern of catch-up growth in CRF. Changes
in growth velocity are associated to modifications in the
structure and dynamics of growth cartilage.
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Growth retardation is still a major manifestation of children
with chronic renal failure (CRF). The 2005 Annual Report of
the North American Pediatric Renal Transplant Cooperative
Study (NAPRTCS)1 indicates that 36% of 5827 children
younger than 21 years with CRF have height Z-score worse
than 1.88. Except in the group of infants younger than
1 year of age, the height Z-score does not improve after a
follow-up period of 24 months. As also shown by the
NAPRTCS report,1 the vast majority of children with CRF
have a height below the 50th percentile. This suggests a loss of
potential to achieve the genetically determined final height
that occurs not only in patients with advanced stages of CRF
but also in children with mild–moderate degrees of CRF.
The typical growth pattern of a child with congenital
CRF whose adult height becomes stunted comprises two
periods, infancy and puberty, during which the height deficit
worsens, that is, there is a further deviation from the normal
percentiles, and the mid-childhood period during which the
growth rate parallels the normal growth channel.2,3 This
pattern suggests that the ability to accelerate growth velocity
is reduced in individuals with CRF.
The subtotally nephrectomized young rat is commonly
used as experimental model of growth retardation in CRF.4
Whereas longitudinal growth rate of rats with severe degrees
of CRF is sustainedly lower than that of sham-operated
animals fed ad libitum, rats with milder reductions of renal
function exhibit reduced growth rate only during few
days following the second stage nephrectomy.5 Thereafter,
their growth rate parallels that of control animals. In these
rats with mild–moderate CRF, decreased length gain coexists
with longitudinal growth velocity not different from that
of controls.
The term catch-up growth, introduced by Prader et al.,6
describes the phenomenon by which longitudinal growth
velocity transiently stands above the statistical limits of
normality for age and/or maturity after the removal of a
growth-inhibiting condition. It has been observed in humans
and animals and its underlying pathogenic mechanism is
not clear.7,8
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The study presented here was designed to determine if the
ability to exhibit catch-up growth is preserved in CRF as well
as to know its characteristics, associated changes in long bone
growth plate and the effect of growth hormone (GH)
treatment. It was hypothesized that individuals with CRF
are able to keep a ‘normal’ longitudinal growth rate but have
a reduced potential to increase growth velocity following a
growth-inhibiting condition. In addition, GH treatment,
which has been shown to accelerate growth velocity of
subjects with CRF,9,10 might likely modify the pattern of
catch-up growth in CRF.
RESULTS
On day 4, weight and length of animals were not different
among groups: C (74.470.9 g, 22.670.2 cm), CR (73.27
1.0 g, 22.870.1 cm), CRGH (77.071.6 g, 22.870.3 cm), Nx
(71.471.1 g, 22.670.2 cm), NxR (71.770.9 g, 22.87
0.2 cm), NxRGH (73.770.7 g, 23.170.2 cm). Data on serum
urea nitrogen (SUN), serum creatinine, body weight, and
length gain in animals killed at different time points of the
protocol are given in Table 1. Renal function was significantly
and similarly reduced in the three groups of nephrectomized
rats. Food restriction decreased length gain on day 14. Length
gain of animals subjected to diet restriction became
practically identical to their corresponding control groups
on day 21 for those groups treated with GH and on day 36
for the untreated groups.
Longitudinal bone growth rates assessed by daily osseous
front advances at the different time points of the study are
shown in Table 2. Catch-up growth was demonstrated on day
21 in CR, CRGH, and NxRGH groups and on day 36 in NxR
rats. Representative images of calcein labeling to illustrate
greater osseous front advance in NxRGH and NxR groups
than C rats are shown in Figure 1a.
Histomorphometry of growth cartilage and index of
proliferating chondrocytes on days 21 and 36 of the protocol
are summarized in Tables 3 and 4. Representative images are
shown in Figure 1b and c. In addition, no differences were
found in the pattern of expression of platelet/endothelial
cell adhesion molecule-1 (PECAM-1) or vascular endothelial
growth factor (VEGF), as revealed by immunohistochemistry,
among the groups. PECAM-I was expressed in the hyper-
trophic zone with a clear intracellular signal that was mildly
weaker in the area next to the primary spongiosa (data not
shown). By contrast, VEGF was mainly expressed in the most
distal chondrocytes (data not shown). In situ hybridization
showed signal for collagen X mRNA confined to the hyper-
Table 1 | Renal function and growth of animals (n=5 per
group) killed at the different time points of the protocol
SUN
(mg/dl)
Creatinine
(mg/dl)
Weight
(g)
Length gain
(cm)
Day 14
C 1270 0.470.0 130.773.4 6.170.3
CR 970 0.470.0 108.272.9a 5.170.2a
Nx 2872a,b 0.770.1a,b 117.675.2 4.870.2a
NxR 3072a,b 0.770.1a,b 91.873.4a,b,c 3.770.2a,b,c
Day 17
C 1171 0.370.0 136.371.8 6.770.3
CR 1171 0.370.0 127.671.2 6.270.3
CRGH 1370 0.370.0 137.073.5 6.470.2
Nx 3273a,b,d 0.770.1a,b,d 131.074.2 6.070.4
NxR 2772a,b,d 0.570.0a,b,d 120.373.4 5.170.3a
NxRGH 2971a,b,d 0.570.0a,b,d 129.275.1 5.370.4
Day 21
C 1471 0.370.0 145.173.1 8.170.3
CR 1171 0.370.0 146.072.2 7.870.2
CRGH 1471 0.470.0 164.476,5a,b 8.270.3
Nx 3171a,b,d 0.670.0a,b,d 144.473.5d 7.770.2
NxR 3071a,b,d 0.570.0a,b,d 134.672.4d 6.870.2a,d
NxRGH 2470a,b,c,d,e 0.670.0a,b,d 155.273.5e 7.670.2
Day 36
C 1170 0.470.0 188.875.4 11.770.4
CR 1171 0.470.0 191.075.9 11.870.1
Nx 2672a,b 0.770.0a,b 183.572.9 11.170.3
NxR 2572a,b 0.770.0a,b 185.074.7 11.170.3
GH, growth hormone.
SUN means serum urea nitrogen. C means control group. CR means normal renal
function group undergoing diet restriction from days 11 to 13. CRGH means normal
renal function group undergoing diet restriction from days 11 to 13 and treated
with GH from day 14 until killing. Nx means chronic renal failure group. NxR means
chronic renal failure group undergoing diet restriction from days 11 to 13. NxRGH
means chronic renal failure group undergoing diet restriction from days 11 to 13
and treated with GH from day 14 until killing. Length gain means body length
increment between day 4 and the corresponding day of killing.
Data are mean7s.e.m.
aSignificantly different from C.
bSignificantly different from CR.
cSignificantly different from Nx.
dSignificantly different from CRGH.
eSignificantly different from NxR.
Table 2 | Osseous front advance (lm/day) in the different groups of animals (n=5 per group) according to the moment of killing
C CR CRGH Nx NxR NxRGH
Day 14 250.476.2 229.073.5 NA 243.873.8 202.579.9 NA
Day 17 223.874.1 172.974.2 182.276.3 191.776.5 146.7710.5 144.579.5
Day 21 164.577.7 186.176.1a 201.174.4a 193.077.5 173.373.9 201.276.0a
Day 36 91.571.1 95.673.0 NA 97.672.0 118.872.7a NA
GH, growth hormone; NA, not available.
Catch-up growth was observed on day 21 in CR, CRGH, and NxRGH groups and on day 36 in NxR animals.
C means control group. CR means normal renal function group undergoing diet restriction from days 11 to 13. CRGH means normal renal function group undergoing diet
restriction from days 11 to 13 and treated with GH from day 14 until killing. Nx means chronic renal failure group. NxR means chronic renal failure group undergoing diet
restriction from days 11 to 13. NxRGH means chronic renal failure group undergoing diet restriction from days 11 to 13 and treated with GH from day 14 until killing.
Data are mean7s.e.m.
aSignificantly greater than C.
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Figure 1 | Representative histological images of the tibial growth plate in the different groups of animals. (a) Longitudinal bone growth
rate, assessed by the measurement of osseous front advance, in the two moments of the study when catch-up growth was observed in chronic
renal failure rats subjected to diet restriction between days 11 and 13 of the protocol. In growth hormone treated (NxRGH) and untreated (NxR)
animals, the distance between the calcein front and the metaphyseal end of growth cartilage, limits indicated by the two horizontal lines, was
greater than in control (C) animals, indicating the occurrence of catch-up growth, on days 21 and 36 of the protocol, respectively. Photographs
taken from methylmethacrylate-embedded sections of proximal tibia. Bar¼ 100mm. (b) Morphological aspect of growth cartilage of chronic
renal failure rats subjected to diet restriction between days 11 and 13 when catch-up growth was observed in growth hormone-treated
(NxRGH, day 21) or untreated (NxR, day 36) groups. In both time points, catch-up growth was associated with expansion of cartilage height and
its hypertrophic stratum, the differences being more apparent in growth hormone-treated rats. Nx means chronic renal failure group not
subjected to diet restriction. Photographs taken from methylmethacrylate-embedded sections of proximal tibia stained with alzian blue and
safranine. Bar¼ 100 mm. (c) Proliferative activity assessed by immunohistochemical detection of bromodesoxiuridine labeled nuclei – brown
nuclei – in growth cartilage of animals when catch-up growth was observed in chronic renal failure rats subjected to diet restriction between
days 11 and 13 of the protocol and treated (NxRGH, day 21) or untreated (NxR, day 36) with growth hormone. Differences in the index of
proliferating chondrocytes were not detected. Nx means chronic renal failure group. Photographs taken from methylmethacrylate-embedded
sections of proximal tibia. Bar¼ 100 mm. (d) In situ hybridization for collagen X mRNA in growth cartilage of the different groups of rats on day
21 of the protocol. The pattern of expression was essentially the same in all groups although in rats treated with GH the signal seemed to be
more evident in the most distal rows of chondrocytes. C means control group. CR means normal renal function group subjected to diet
restriction from days 11 to 13. CRGH means normal renal function group subjected to diet restriction from days 11 to 13 and treated with
growth hormone from days 14 to 20. NxR means chronic renal failure group subjected to diet restriction from days 11 to 13. NxRGH means
chronic renal failure group subjected to diet restriction from days 11 to 13 and treated with growth hormone from days 14 to 20. Photographs
taken from methylmethacrylate-embedded sections of proximal tibia. Bar¼ 100mm.
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trophic stratum with attenuation or disappearance of the
signal in the two o three rows of chondrocytes adjacent to the
metaphyseal bone. In rats treated with GH, the collagen
X mRNA signal was homogenous along the hypertrophic
zone, the signal being clearly appreciable in the row of cells
contiguous to bone (Figure 1d).
DISCUSSION
An outstanding finding of this study was that the two groups
of animals undergoing diet restriction, either with normal or
reduced renal function, showed complete catch-up growth in
body length returning precisely to the length of their
corresponding control groups. Full catch-up longitudinal
growth to the small size of non-fasted individuals, has been
observed in rats and rabbits treated with corticosteroids11,12
and in head-irradiated13 rats following fasting. Our study
indicates that rats with mild–moderate renal failure retain the
ability to accelerate longitudinal growth velocity and recover
their former growth curve after removal of an additional
growth-inhibiting condition. The mechanisms controlling
the phenomenon of catch-up growth are still unknown.
Tanner14 proposed the hypothesis that catch-up growth is
regulated by a central nervous system mechanism that
compares the individual’s actual size to an age-appropriate
set point and then adjusts the growth rate accordingly. In
CRF, the set point would be reset to a lower level explaining
why the animals of the present study reassumed the growth
curve that they were following before the injury. It has
alternatively been proposed that the mechanism governing
catch-up growth is intrinsic to the growth plate15 and
that catch-up growth is due, at least in large part, to a delay
in growth plate senescence.15,16 According to this hypothesis,
growth plate chondrocytes have a limited and programmed
proliferative capacity that determines the growth rate and,
when the number of replications is exhausted, the end of
longitudinal growth. A growth inhibiting condition transi-
ently interrupts or slows chondrocytes’ proliferative activity,
which is reassumed when the aggression ceases resulting in a
greater growth rate than expected for age. In the light of this
hypothesis, the inability of the nephrectomized rats to
achieve a normal length after removal of food restriction
could be justified by the persistence of CRF-related growth-
inhibiting factors.7
It is also of note that the pattern of catch-up growth was
markedly different in CRF and normal renal function rats.
Firstly, acceleration of growth rate occurred much later in the
nephrectomized rats. Osseous front advance of these animals
became higher than that of control rats on day 36 of the
protocol, whereas in rats without renal insufficiency catch-
up growth was demonstrated on day 21 of the protocol.
Secondly, catch-up growth took place at much higher growth
velocity in rats with normal renal function. The differences in
chronology and maximum osseous front advance suggest
that CRF limits the potential to reach a marked increment of
growth rate and catch-up growth is delayed until periods
where the longitudinal growth velocity is physiologically
slow. This reduced potential to maximally accelerate growth
might be present in children with early-onset chronic renal
insufficiency and explain why height retardation of these
patients worsens in infancy and puberty, periods of life where
growth velocity is normally very high.2
The phenomenon of catch-up growth was accompanied
by expansion of growth cartilage and its hypertrophic zone in
rats with normal renal function as well as in rats with CRF.
The height of growth cartilage columns is the result of the
Table 3 | Characteristics of growth cartilage in the animals (n=5 per group) killed on day 21 of the protocol
C CR CRGH Nx NxR NxRGH
Growth cartilage height (mm) 381711 404716a 451713a,b 40678 41577 47379c,d
Hypertrophic zone height (mm) 23077 244710a 268713a 23976 23376 284710c,d
Terminal chondrocyte height (mm) 3070 3071 3271a,b 3071 3071 3371c,d
Proliferating chondrocytes (cells/100 columns) 181714 282715a 296712a 23378 252711 230714
GH, growth hormone.
Catch-up growth (groups CR, CRGH, and NxRGH) was associated with changes in cartilage morphology and cell proliferation.
C means control group. CR means normal renal function group undergoing diet restriction from days 11 to 13. CRGH means normal renal function group undergoing diet
restriction from days 11 to 13 and treated with GH from days 14 to 20. Nx means chronic renal failure group. NxR means chronic renal failure group undergoing diet
restriction from days 11 to 13. NxRGH means chronic renal failure group undergoing diet restriction from days 11 to 13 and treated with GH from days 14 to 20.
Data are mean7s.e.m. Comparisons between groups were performed within normal renal function or nephrectomized groups.
aSignificantly different from C.
bSignificantly different from CR.
cSignificantly different from Nx.
dSignificantly different from NxR.
Table 4 | Characteristics of growth cartilage in the animals
(n=5 per group) killed on day 36 of the protocol
C CR Nx NxR
Growth cartilage height (mm) 240711 25279 26876 29279a
Hypertrophic zone height (mm) 11678 12076 12573 14875a
Terminal chondrocyte
height (mm)
2471 2470 2471 2571
Proliferating chondrocytes
(cells/100 columns)
152714 188710 202710 180723
Catch-up growth (groups NxR) was associated with changes in cartilage morpho-
logy.
C means control group. CR means normal renal function group undergoing diet
restriction from days 11 to 13. Nx means chronic renal failure group. NxR means
chronic renal failure group undergoing diet restriction from days 11 to 13.
Data are mean7s.e.m. ANOVA was below or equal to 0.001 for each parameter.
Comparisons between groups were performed within normal renal function or
nephrectomized groups.
aSignificantly different from Nx.
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dynamic equilibrium between two vectors. One goes from
diaphysis to epiphysis and represents bone apposition. The
other one goes in opposite sense and represents cartilage
formation and progression.17 The increased size of the
columns of chondrocytes suggests a transient disequilibrium
between these two vectors so that the vector representing
chondrogenesis increased more than that of new bone
apposition. In normal renal function rats, catch-up growth
was associated with a significant increment of chondrocyte
proliferating activity, which could not be demonstrated in
renal failure rats. This is consistent with the assumption
that in the setting of renal failure, the process of catch-up
growth is delayed and occurs with slower growth velocities.
Likewise, the less marked increase of cartilage height
associated to catch-up growth in nephrectomized animals
also suggests that the process of catch-up growth occurs more
gradually in CRF.
The effect of GH was evident in rats killed on day 21 of the
protocol, after 1 week of treatment. GH accelerated growth
rate in rats with normal renal function and with renal failure
as well. This finding agrees with previous clinical and
experimental studies demonstrating the growth promoting
effect of GH in CRF.9,10 The effect of GH treatment was
associated with improved food efficiency (0.3370.01 g of
weight gained/g of food ingested from days 14 to 21 in
NxRGH vs 0.2870.01 g in NxR, Po0.05) but not stimula-
tion of food intake (135.073.9 vs 127.774.7 g in both
groups over the same period of time). It is interesting to note
that GH treatment normalized the pattern of catch-up
growth in nephrectomized rats so that catch-up occurred
earlier, at the same time as rats with normal renal function,
and with much greater growth rate than the group of
untreated diet restricted CRF rats. It should be pointed out
that catch-up growth induced by GH was associated with
increased height of growth cartilage and its hyper-
trophic zone as well as that of the distal chondrocytes. The
expansion of growth cartilage has formerly been reported in
uremic rats treated with GH10,18 and may reflect a transiently
greater stimulus of GH on chondrogenesis than on new
bone apposition. In normal renal function GH-treated rats,
acceleration of growth rate was accompanied by an increase
in the proliferative activity of chondrocytes that could
not be demonstrated in GH-treated rats with renal
insufficiency. However, in this group, GH administration
seemed to exert a beneficial effect on the process of
maturation and hypertrophy of the chondrocytes as shown
by enlargement of most distal chondrocytes and extension
of collagen X mRNA expression up to the terminal rows of
chondrocytes. Former in situ hybridization studies have
reported unchanged19,20 and decreased21,22 collagen X mRNA
expression in the hypertrophic zones of uremic rat growth
plates as well as increased expression following GH
treatment.21 The patterns of expression in the hypertrophic
chondrocytes of PECAM-1, peptide with potent antiapopto-
tic properties,23 and VEGF, angiogenic factor that is supposed
to play an important role in the process of endochondral
bone formation,24 were essentially unchanged in the different
groups of animals.
Finally, the characteristics of the experimental model
obtained in this study deserve some comments. Female rats
were chosen because it has been shown that respond better to
GH treatment.10 The rats with CRF had similar degree of
renal function reduction as reflected by the lack of difference
in SUN and serum creatinine concentrations among the three
groups of nephrectomized rats. On day 21, NxRGH rats had
lower SUN values, this difference being likely related to the
well-known anabolic effect of GH therapy. Although renal
failure was not severe, nephrectomized rats were growth
retarded in comparison with the control group, as confirmed
by lower length gains in Nx rats than in rats with normal
renal function on day 14 of the protocol. Importantly, growth
retardation coexisted with a growth rate at the moment
of killing not different from that of controls. This agrees
with former studies showing that, after nephrectomy, growth
retardation worsens only in young nephrectomized rats with
SUN concentrations greater than 3–4 times normal values,
whereas animals with milder degrees of renal failure become
stunted as a result of the surgical stress and subsequent acute
renal failure but their further growth velocity is not different
from controls.5 In these animals, the adverse effect of
mild CRF on growth becomes manifest by the inability to
return to the normal growth percentiles. Achieving a model
of growth retardation with normal growth rate was a goal of
the experimental design because it cannot be expected that
animals unable to maintain a normal basal growth rate are
capable of undergoing catch-up growth. Diet restriction
slowed growth rate as shown by reductions of osseous front
advance of 17 and 9% in NxR and CR groups, respectively,
in comparison with their corresponding diet unrestricted
groups. Thus, identical percentage of food intake reduction
caused a greater adverse effect on growth velocity in animals
with CRF.
In summary, the study presented here shows that the
ability to undergo catch-up growth after a transient growth-
inhibiting condition is preserved in an experimental model
of moderate CRF. However, the pattern of catch-up
growth differs markedly from that observed in individuals
with normal renal function. In renal failure, catch-up growth
occurs later and with slower growth rates. Regardless renal
function, marked modifications in the structure and
dynamics of growth plate are associated with the catch-up
growth phenomenon. Administration of GH normalizes the
pattern of catch-up growth in rats with CRF and, at the same
time, seems to exert a beneficial effect on the process of
maturation and hypertrophy of chondrocytes.
MATERIALS AND METHODS
Animals
The experiments conducted complied with current legislation on
animal experiments in the European Union and were approved
by our Institution’s Ethics Committee for Investigation with
Animals.
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Female Sprague–Dawley rats of 25 days of age and weight of
5676 g were purchased (Harlan Interfauna Ibe´rica SL, Barcelona,
Spain) and housed in individual cages at room temperature between
22 and 241C and 12-h light–dark cycle. Rats received standard
diet containing 17.2% of proteins and 3100 kcal/kg (PANLAB SA,
Barcelona, Spain) and had free access to tap water. After 4 days of
acclimation to the experimental area the animals were grouped
as follows: normal renal functionþ no diet restriction (C); normal
renal functionþ diet restriction (CR); normal renal functionþ diet
restrictionþGH treatment (CRGH); CRFþ no diet restriction
(Nx); CRFþ diet restriction (NxR); CRFþ diet restrictionþGH
treatment (NxRGH).
Animals were killed (n¼ 5) on different days of the protocol.
Day 14: groups C, CR, Nx, and NxR; day 17: groups C, CR, CRGH,
Nx, NxR, and NxRGH; day 21: groups C, CR, CRGH, Nx, NxR, and
NxRGH; day 36: groups C, CR, Nx, and NxR.
Experimental protocol
Days 0 and 4: two stage subtotal nephrectomy or sham operation.9
From day 4 until killing: daily measurement of body weight
and food consumption from days 11 to 13: 3-day diet restriction
to the appropriate groups which received 50% of the average
daily food consumed by the same animals the 3 previous days (from
days 8 to 10).
From day 14 onward: removal of diet restriction.
From days 14 to 16 (protocol of 17 days) or from days 14 to 20
(protocol of 21 days), 10 IU/kg/day of intraperitoneal recombinant
human GH (Norditropin, Novo Nordisk Pharma, Madrid, Spain)
was administered at 0009 and 1700 hours, approximately, to CRGH
and NxRGH groups. Untreated animals received the same volume of
solvent (saline).
Rats received 2 mg/100 g body weight of calcein (Sigma-Aldrich
Spain, Tres Cantos, Madrid, Spain) solved in saline and sodium
bicarbonate by intraperitoneal route 72 h before killing.
Rats received three intraperitoneal doses of 5-bromo-20-deso-
xiuridine (BrdU) at 10 mg/100 g body weight (Sigma-Aldrich Spain)
60 min, 9, and 17 h before killing.
Days 0, 4, and immediately before killing: Measurement of snout
to tail tip length with a ruler. The gain in body length was calculated
for each time of the study.
Tissue samples were obtained at killing, which was carried out by
exsanguination under anesthesia.
Samples
Serum samples were stored at 201C until measurement of SUN
and creatinine with a Kodak Ektachem DT60 analyzer (Rochester,
NY, USA). Tibiae were removed and processed as follows. Imme-
diately after killing, the proximal end of the tibiae, including the
growth plate, was dissected out. The right tibia was fixed in 40%
ethanol for analysis of calcein labeling and BrdU immunohisto-
chemistry. The left tibia was fixed in 4% neutral formalin at 41C, for
morphometric analysis, VEGF, and PECAM-1 immunohistochem-
istry as well as for collagen X in situ hybridization. Then, both tibiae
were dehydrated in graded solutions of ethanol and embedded in
methylmethacrylate as described formerly.25,26
Measurement of longitudinal growth rate
Frontal 10-mm thick sections of proximal end of tibiae were
obtained using a rotary microtome (HM355S, Microm, Barcelona,
Spain) fitted with tungsten carbide blades. Sections were examined
under an Olympus incident light fluorescence microscope (Olympus
BX41) coupled to a digital camera (Olympus DP11, Olympus
Optical Espan˜a, Barcelona, Spain) to detect calcein label. Images
were captured and the distance between the chondro-osseous
junction and the calcein label was measured using an image analysis
system (Scion Image, Scion Corporation, Frederick, MD, USA).
The average value of these measurements divided by 3 (days) was
considered the osseous front advance per day, representing the daily
longitudinal bone growth rate in each animal. Catch-up growth was
considered to occur in a group of rats when their longitudinal bone
growth rate, assessed by osseous front advance as detailed above, was
significantly greater than that of control animals with normal renal
function and not subjected to former diet restriction (group C).
Measurement of proliferative activity of chondrocytes, histo-
morphometry, immunohistochemistry, and in situ hybridization
studies were performed in growth cartilage sections obtained at
those times of the protocol when catch-up growth was detected.
Index of proliferating chondrocytes
Frontal 5-mm thick sections of proximal end of tibiae were incubated
for 15 min in fresh 100% acetone to remove methylmethacrylate.
After hydration, sections were incubated in HCl (2 N, 60 min, 371C),
thoroughly washed in water, rinsed in 0.1 M Tris-hydrochloric buffer,
and treated with trypsin (1 mg/ml, 1% CaCl2; 60 min, 371C). After
several washes in Tris-hydrochloric buffer, endogenous peroxidase
activity was inactivated by 30-min treatment in 0.6% hydrogen
peroxide. Samples were incubated with horse serum (1:50, 75 min;
Sigma-Aldrich), followed by 48-h incubation with monoclonal
antibody to BrdU (1:20; Dako Diagnosticos SA, Barcelona, Spain)
in moist chamber at 41C. Then, sections were incubated at room
temperature with an anti-mouse IgG biotin conjugate (1:200,
60 min; Sigma-Aldrich) and ExtrAvidin (3:100, 45 min; Sigma-
Aldrich). The final reaction product was revealed with 3-30-
diaminobenzidine (Sigma-Aldrich), 10 mg of 3-30-diaminobenzi-
dine in 50 ml of 0.05 M Tris-hydrochloric buffer plus 50 ml of 0.3%
hydrogen peroxide. Preparations were lightly counterstained
with alzian blue. The number of BrdU-positive cells per column
of chondrocytes was counted as well as the number of columns per
field. Six fields per section and two sections per animal were
measured. For each animal, proliferative activity was expressed as
the mean number of BrdU-labeled cells per 100 columns.
Morphometric analysis of growth plate
Heights of growth cartilage and its hypertrophic zone as well as
height and area of the three most distal hypertrophic chondrocytes
were measured in 5 mm thick sections stained with alzian blue and
safranine at 20 randomly selected locations on each section, using
the above-mentioned image analysis system.
Immunohistochemical analysis for PECAM-1 and VEGF
Immunohistochemical staining for PCAM-1 or VEGF was per-
formed in formalin-fixed sections. After deplastination in acetone
and rehydration as before, the sections for PCAM-1 analysis were
heated in buffer citrate (pH 6.0, 801C, 45 min). Then, all sections
were treated with 3% hydrogen peroxide and 25% goat serum and
incubated overnight (18 h) at 41C with 1/100 solution of PECAM-1
antibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
or 6/100 polyclonal anti-VEGF (Neo Markers, Westinghouse,
CA, USA). After 30-min incubation with anti-rabbit secondary
conjugated antibody (En VisionþTM; Dako Diagnosticos), the
final reaction product was revealed with 3-30-diaminobenzidine
(Sigma-Aldrich); 20 mg of 3-30-diaminobenzidine in 50 ml of 0.05 M
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Tris-hydrochloric buffer plus 50 ml of 30% hydrogen peroxide.
Sections were counterstained with alzian blue.
In situ hybridization for collagen X
The collagen X antisense and sense RNA probes were supplied by
Genedect (Genedetect.com, Bradenton, FL, USA). For the hybridi-
zation procedure, guidelines of the supplier were followed. After
hydration, sections were treated with triethanolamine (0.1 M) and
acetic anhydride for 16 min and 300mg/ml proteinase K for 30 min
at 501C, fixed in 4% paraformaldehyde, and washed in phosphate-
buffered saline for 5 min twice. Prehybridation was performed
for 2 h at 401C. Hybridization was performed overnight at 401C in
moist chamber. After washing in 1 standard sodium citrate at
room temperature, and 1 standard sodium citrate and 0.5
standard sodium citrate at 551C, nonspecific binding was blocked
by 1% blocking buffer (Blocking Reagent, Boehringer, Manheim,
GmbH, Germany) in Tris buffered saline for 30 min. Slides were
placed in a moist chamber and incubated overnight with alkaline
phosphatase-conjugated anti-digoxigenine (1:1000; Boehringer) in
Tris buffered saline at 41C. After three washes (5 min each) in
Tris buffered saline, alkaline phosphatase was then revealed
with a substrate solution containing 0.16 mg/ml 5-bromo-4-chloro-
3-indolylphosphatase (Sigma-Aldrich) and 0.33 mg/ml nitroblue
tetrazolium (Sigma-Aldrich) in 1 M Tris buffer. The enzymatic
reaction was stopped with distilled water for several minutes and
mounted with glycergel (Dako Diagnosticos). Two parallel sections
served as negative controls. One section hybridized with a labeled-
sense riboprobe and a second section incubated without adding any
probe to the hybridization mixture. No hybridization signal was
found in any of these negative controls.
Statistical analysis
Values for each group are given as mean7s.e.m. For comparisons,
the four time points of the protocol (14, 17, 21, and 36 days) were
considered as independent studies. Comparisons among groups
were performed by analysis of variance after confirming the normal
distribution of the values by means of the Kolmogorov–Smirnov and
Shapiro–Wilks test. Comparisons between two groups were
performed by the Bonferroni corrected Student’s t-test when
appropriate. A P-value above 0.05 was considered as indicative of
significant difference. Calculations were carried out by using SPSS
11.0 software (SPSS Inc. Headquarters, Chicago, IL, USA).
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